Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Survival
/ drug effects
Curcumin
/ pharmacology
Drug Carriers
/ administration & dosage
Drug Delivery Systems
/ methods
Female
Humans
Lipids
/ administration & dosage
MCF-7 Cells
Nanoparticles
/ administration & dosage
Particle Size
Radiation-Sensitizing Agents
/ pharmacology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 07 2019
31 07 2019
Historique:
received:
17
01
2019
accepted:
10
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
29
10
2020
Statut:
epublish
Résumé
In breast cancer (BC) care, radiotherapy is considered an efficient treatment, prescribed both for controlling localized tumors or as a therapeutic option in case of inoperable, incompletely resected or recurrent tumors. However, approximately 90% of BC-related deaths are due to the metastatic tumor progression. Then, it is strongly desirable to improve tumor radiosensitivity using molecules with synergistic action. The main aim of this study is to develop curcumin-loaded solid nanoparticles (Cur-SLN) in order to increase curcumin bioavailability and to evaluate their radiosensitizing ability in comparison to free curcumin (free-Cur), by using an in vitro approach on BC cell lines. In addition, transcriptomic and metabolomic profiles, induced by Cur-SLN treatments, highlighted networks involved in this radiosensitization ability. The non tumorigenic MCF10A and the tumorigenic MCF7 and MDA-MB-231 BC cell lines were used. Curcumin-loaded solid nanoparticles were prepared using ethanolic precipitation and the loading capacity was evaluated by UV spectrophotometer analysis. Cell survival after treatments was evaluated by clonogenic assay. Dose-response curves were generated testing three concentrations of free-Cur and Cur-SLN in combination with increasing doses of IR (2-9 Gy). IC
Identifiants
pubmed: 31366901
doi: 10.1038/s41598-019-47553-2
pii: 10.1038/s41598-019-47553-2
pmc: PMC6668411
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Lipids
0
Radiation-Sensitizing Agents
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11134Références
BMC Cancer. 2013 Jan 29;13:37
pubmed: 23356739
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Neurochem Int. 2015 Oct;89:234-42
pubmed: 26254982
J Agric Food Chem. 2017 Feb 22;65(7):1342-1352
pubmed: 28111949
Crit Rev Food Sci Nutr. 2018 May 24;58(8):1271-1293
pubmed: 27874279
Exp Ther Med. 2017 Dec;14(6):5896-5902
pubmed: 29285138
Exp Ther Med. 2018 Apr;15(4):3650-3658
pubmed: 29545895
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165
OMICS. 2013 Mar;17(3):119-29
pubmed: 23421906
Biomed Res Int. 2015;2015:363671
pubmed: 26539482
Cancer Prev Res (Phila). 2011 Oct;4(10):1698-709
pubmed: 21836020
Mol Med Rep. 2016 Mar;13(3):2187-93
pubmed: 26781771
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):840-8
pubmed: 15728539
Mol Cell Biochem. 2013 Nov;383(1-2):39-48
pubmed: 23846485
J Clin Oncol. 2007 Aug 1;25(22):3259-65
pubmed: 17577015
J Radiat Res. 2012 Jul;53(4):633-40
pubmed: 22843631
Mol Syst Biol. 2011 Aug 16;7:523
pubmed: 21847114
Cancer Lett. 2015 Aug 28;365(1):122-31
pubmed: 26004342
Mol Syst Biol. 2015 Jan 21;11(1):775
pubmed: 25609649
Cancer Lett. 2008 Oct 8;269(2):199-225
pubmed: 18479807
Mol Nutr Food Res. 2017 Mar;61(3):
pubmed: 27990751
Mol Biosyst. 2015 Mar;11(3):859-68
pubmed: 25578635
Nanomedicine (Lond). 2017 Oct;12(19):2287-2302
pubmed: 28868971
Autophagy. 2012 May 1;8(5):812-25
pubmed: 22622204
Eur J Pharmacol. 2011 Oct 1;668(1-2):127-32
pubmed: 21762689
Cancer Res. 2007 Mar 1;67(5):1988-96
pubmed: 17332326
Int J Chron Obstruct Pulmon Dis. 2016 Nov 07;11:2765-2773
pubmed: 27853364
Adv Exp Med Biol. 2007;595:301-20
pubmed: 17569217
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Eur J Surg Oncol. 2013 Jun;39(6):613-8
pubmed: 23523088
Mol Cancer. 2011 Feb 07;10:12
pubmed: 21299897
Aging (Albany NY). 2011 Nov;3(11):1098-109
pubmed: 22156377
Eur J Med Chem. 2018 Aug 5;156:493-509
pubmed: 30025345
Mol Med Rep. 2016 May;13(5):3763-70
pubmed: 27035875
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):815-21
pubmed: 22417805
Comput Biol Med. 2017 Oct 1;89:454-465
pubmed: 28886482
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Feb 5;190:89-95
pubmed: 28915469
Biochem Pharmacol. 2005 Sep 1;70(5):700-13
pubmed: 16023083
J Pharmacol Sci. 2013;121(4):247-56
pubmed: 23603894
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e153-8
pubmed: 21664063
Cancer Res. 2014 Mar 15;74(6):1682-93
pubmed: 24448243
Oncogene. 2004 Feb 26;23(8):1599-607
pubmed: 14985701
Cancer Cell Int. 2014 Nov 30;14(1):126
pubmed: 25530715
Carcinogenesis. 2007 Feb;28(2):233-9
pubmed: 17151090
Genome Med. 2011 Aug 23;3(8):52
pubmed: 21861849
Oncol Rep. 2016 May;35(5):2615-23
pubmed: 26985708
Mol Cell Endocrinol. 2018 Oct 15;474:127-136
pubmed: 29499209
Anticancer Res. 2015 Jun;35(6):3223-34
pubmed: 26026082
Anticancer Res. 2015 May;35(5):2577-91
pubmed: 25964533
Oncotarget. 2016 Aug 23;7(34):54883-54896
pubmed: 27448972
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):890-8
pubmed: 16751071